FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
 
 
TXT FDA Postpones Domestic Surveillance Inspections
03/18/2020
 
 
TXT FDA Looks at Repurposing Older Drugs for Outbreak
03/19/2020
 
 
TXT Some Adverse Event Reporting Relaxed Under Pandemic
03/20/2020
 
 
TXT Trump Promises More FDA Virus Actions
03/18/2020
 
 
TXT Sen. Warner Wants Drug Making Moved Back to U.S
03/16/2020
 
 
TXT Conducting Clinical Trials During Pandemic
03/18/2020
 
 
TXT FDA Loses Eagle Orphan Drug Appeal
03/18/2020
 
 
TXT CGMP Violations at India’s Cipla Limited
03/17/2020
 
 
TXT Stakeholders Seek Changes in Effectiveness Guidance
03/19/2020
 
 
TXT More Pediatric Oncology Guidance Info Sought
03/18/2020
 
 
TXT Coronavirus Testing Improving This Week: Gottlieb
03/16/2020
 
 
TXT Latest Federal Register Notices
03/22/2020
 
 
TXT Since Our last Issue...
03/22/2020
 
 
TXT Product Approval Summaries
03/22/2020
 
 
TXT FDA Update on Painkillers Worsening Virus
03/20/2020
 
 
TXT FDA Rejects Boehringer/Lilly Diabetes NDA
03/20/2020
 
 
TXT 2 Guidances on Making Hand Sanitizers
03/20/2020
 
 
TXT FDA Clears Remote Monitors Temporary Expanded Use
03/20/2020
 
 
TXT 17 Issues In Invitrx Inspection
03/19/2020
 
 
TXT FDA Looks for Coronavirus Test Info on Twitter
03/19/2020
 
 
TXT CDER Denies NDA ‘Complete Response’ Appeal
03/18/2020
 
 
TXT Preemption Cited in Gadolinium Case
03/18/2020
 
 
TXT FDA Releases ‘Purell’ Warning Letter
03/17/2020
 
 
TXT Liquid Drug Flow Restrictor Guidance
03/17/2020
 
 
TXT Windlas Healthcare Inspection Sees CGMP Issues
03/17/2020
 
 
TXT FDA Gives States Coronavirus Testing Authority
03/17/2020
 
 
TXT Latest FDA Warning Letters
03/17/2020
 
 
TXT Novo Nordisk Halts 3 Hemophilia Trials Over Safety
03/17/2020
 
 
TXT SGLT2 Inhibitor Safety Label Changes
03/17/2020
 
 
TXT FDA Lifts Clinical Hold on Unum Therapy
03/16/2020
 
 
 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving